Inhaled Nitric Oxide Delivery Systems Market Size, Share & Trends Analysis Report By Type (Pediatric, Adult), By Application (HRF, AHRF), By Product (Disposables, Systems), By End User- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global inhaled nitric oxide delivery systems market size was exhibited at USD 247.80 million in 2023 and is projected to hit around USD 487.46 million by 2033, growing at a CAGR of 7.0% during the forecast period of 2024 to 2033.

Inhaled Nitric Oxide Delivery Systems Market Size 2024 To 2033

Key Takeaways:

  • The pediatric segment accounted for the largest revenue share of 77.6% in 2023.
  • Hypoxic Respiratory Failure (HRF) inhaled nitric oxide delivery system held the largest segment share of 80.2% in 2023.
  • The disposables product segment accounted for the largest revenue share of 65.1% in 2023.
  • The hospitals segment captured the highest revenue share of 88.0% in 2023.
  • North America is expected to be the fastest-growing regional market, registering a CAGR of 7.84% during the forecast period.

Inhaled Nitric Oxide Delivery Systems Market Report Scope

 Report Coverage  Details
Market Size in 2024 USD 247.80 Million
Market Size by 2033 USD 487.46 Million
Growth Rate From 2024 to 2033 CAGR of 7.0%
Base Year 2023
Forecast Period 2024-2033
Segments Covered Type, Application, Product, End User, Region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional Scope North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa
Key Companies Profiled Mallinckrodt Pharmaceuticals; Getinge; Vero Biotech; LINDE; Beyond Air; SLE; NU MED; Bellerophon Therapeutics; Air Liquide Healthcare; Circassia Pharmaceuticals.

 

Inhaled Nitric Oxide (INO), a minimally invasive therapy, is proposed to treat conditions associated with reversible pulmonary vasoconstriction and pulmonary hypertension in children and adults. Improved safety and efficacy, a rapid offset of action, reduced toxicity, high concentration of drug at the target organ, avoidance of systemic adverse reaction, and reduced dose of medication are some of the advantages of INO over other medication. This is leading to the improved adoption of INO, potentially driving the market growth.

In vitro studies suggest that INO is effective in suppressing the SARS-CoV-2 virus treating the diseases as efficiently as the current medication. In addition, INO is effective in treating Acute Respiratory Distress Syndrome (ARDS), the main characteristic of COVID-19–positive patients. Furthermore, studies suggest that INO increases the oxygenation within the bloodstream of COVID-positive patients but has no effect on mortality.

Leading market players like Mallinckrodt Pharmaceuticals are demonstrating the inhibitory effect of INO against the SARS-CoV-2 virus. It is proved to be effective in improving blood oxygen levels, reduction in supplemental oxygen, and a reduction in the amount of ventilator support. Further studies by researchers would confirm the benefits of nitric oxide in the treatment of coronavirus. Interestingly, the year 2023, witnessed an alarming need for nitric oxide devices and disposables, however, global lockdowns, closure of supply chains, and lack of raw material availability led to the drop in sales, negatively impacting the market.

Type Insights

The pediatric segment accounted for the largest revenue share of 77.6% in 2023. Inhaled nitric oxide is proved to be the most effective in treating neonatal diseases like hypoxic respiratory failure (HRF). In the U.S. alone, nearly 25,000 to 30,000 neonatal HRF cases are reported annually, and nearly 50% are cured using INO therapy. The average cost of this therapy per hour is nearly USD 150, which accounts for a total of USD 97,000 to 130,000 per patient for 72 to 96 hours.

Hence, to fulfill the large medical expenses, the government in most countries has established favorable reimbursement policies, which improve the adoption of INO therapy in the neonatal segment. Inhaled nitric oxide needs to be administered in large concentrations in most adult-infected diseases, and a lack of clinical evidence has led to the reduced adoption of this therapy in the adult segment.

Application Insights

Hypoxic Respiratory Failure (HRF) inhaled nitric oxide delivery system held the largest segment share of 80.2% in 2023. This disease is mainly observed in pre-term and near-term neonates due to underlining diseased conditions like pneumonia, sepsis, persistent pulmonary hypertension, and others. It affects 2% of all live births and is responsible for >33% of all neonatal mortality. In the United States, HRF is responsible for the deaths of nearly 18 in 1000 babies, and most of them are born prematurely. Studies suggest that INO is the first line of treatment for HRF and is effectively administered for more than 10 days without signs of complication. Studies suggest that INO therapy costs nearly USD 1129.46 per baby affected by HRF. Thus, cost-effectiveness and high treatment efficacy led to the increased adoption of INO therapy, boosting segment growth.

Acute Hypoxemic Respiratory Failure (AHRF) is another critical illness needing INO therapy as a treatment regime. The mortality rate associated with this condition is nearly 30% but moves up to 50% as it develops complications of sepsis leading to multi-organ failure. Thus, local-acting vasodilators like INO have proven to be an effective first-line treatment. Chronic Obstructive Pulmonary Disorder (COPD) and Bronchopulmonary Dysplasia (BPD) are among a few other application areas of INO therapy.

Product Insights

The disposables product segment accounted for the largest revenue share of 65.1% in 2023. On the basis of product, the market is bifurcated into systems and disposables. The presence of a number of manufacturers and increased demand for nebulizer masks in hospitals have led to increased demand for disposables, thereby driving the segment growth.

Factors such as the low cost of raw materials, abundant resource availability, and a large consumer base, are also anticipated to boost segment growth. INO delivery devices are priced at USD 1400-1700, which makes it difficult for low-tier end-user settings to adopt such equipment as they focus on minimizing the bills. Thus, only large-scale hospitals with the availability of skilled staff and numerous ICU beds can acquire INO systems, which, in turn, leads to a lower share of the system segment.

End-user Insights

The hospitals segment captured the highest revenue share of 88.0% in 2023 owing to the ease of delivery, ability to liquidate for establishing INO delivery device and monitor system, a large number of staff to track device operations, and presence of emergency department. On the basis of end user, the market is segmented into hospitals, surgical centers, and clinics.

Inhaled Nitric Oxide Delivery Systems Market Share, By End-use, 2023 (%)

Mortality rates due to ARFare around 30% in the world. Hence, it is essential to provide these patients with life support and critical care, such as that in hospital ICUs. A rise in the number of hospital admissions is leading to the growth of this segment. On the other hand, ambulatory centers and clinics lack the necessary infrastructure and medical budget, which leads to reduced patient admissions and a lower market share of these segments.

Regional Insights

North America is expected to be the fastest-growing regional market registering a CAGR of 7.84% during the forecast period. This growth can mainly be attributed to the increasing incidences of neonatal mortality due to the rising cases of HRF. In the United States alone, the annual number of term and late preterm newborns with HRF is estimated at 80,000. And about 15% of term infants and 29% of late-preterm infants admitted in Neonatal Intensive Care Units(NICU) develop respiratory morbidity.

In addition, a rise in the adoption of INO therapy, favorable government initiative, and the presence of advanced medical infrastructure boosts regional growth. On the other hand, APAC held the largest revenue share in 2023 and will continue the trend during the forecast period due to the growing pediatric population, a rise in the number of patients suffering from respiratory failure, and the presence of local manufacturers of nitric oxide disposables and systems.

Some of the prominent players in the inhaled nitric oxide delivery systems market include:

  • Mallinckrodt Pharmaceuticals
  • Getinge
  • Vero Biotech
  • LINDE
  • Beyond Air
  • SLE
  • NU MED
  • Bellerophon Therapeutics
  • Air Liquide Healthcare
  • Circassia Pharmaceuticals

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global inhaled nitric oxide delivery systems market.

Type

  • Pediatrics
  • Adult

Application

  • Hypoxic Respiratory Failure (HRF)
  • Acute Hypoxemic Respiratory Failure (AHRF)
  • Others

Product

  • Disposables
  • System

End-user

  • Hospitals
  • Ambulatory Centers
  • Clinics

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global inhaled nitric oxide delivery systems size was reached at USD 247.80 million in 2023 and it is projected to hit around USD 487.46 million by 2033.

The global inhaled nitric oxide delivery systems is growing at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2033.

The North America region has accounted for the largest inhaled nitric oxide delivery systems share in 2023.

The major players operating in the inhaled nitric oxide delivery systems market are Mallinckrodt Pharmaceuticals; Getinge; Vero Biotech; LINDE; Beyond Air; SLE; NU MED; Bellerophon Therapeutics; Air Liquide Healthcare; Circassia Pharmaceuticals.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.1.1. Type

1.1.2. Application

1.1.3. Product

1.1.4. End User

1.1.5. Region

1.1.6. Estimates and forecast timeline

1.2. Research Methodology

1.3. Information Procurement

1.3.1. Purchased database

1.3.2. internal database

1.3.3. Secondary sources

1.3.4. Primary research

1.3.5. Details of primary research

1.3.5.1. Data for primary interviews in North America

1.3.5.2. Data for primary interviews in Europe

1.3.5.3. Data for primary interviews in Asia Pacific

1.3.5.4. Data for primary interviews in Latin America

1.3.5.5. Data for Primary interviews in MEA

1.4. Information or Data Analysis

1.4.1. Data analysis models

1.5. Market Formulation & Validation

1.6. Model Details

1.6.1. Commodity flow analysis (Model 1)

1.6.1.1. Approach 1: Commodity flow approach

1.6.2. Volume price analysis (Model 2)

1.6.2.1. Approach 2: Volume price analysis

1.7. List of Secondary Sources

1.8. List of Primary Sources

1.9. Objectives

1.9.1. Objective 1

1.9.2. Objective 2

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.2.1. Type outlook

2.2.2. Application outlook

2.2.3. Product outlook

2.2.4. End-use outlook

2.2.5. Regional outlook

2.3. Competitive Insights

Chapter 3. Inhaled Nitric Oxide Delivery System Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent market outlook

3.1.2. Related/ancillary market outlook

3.2. Penetration & Growth Prospect Mapping

3.3. Industry Value Chain Analysis

3.3.1. Reimbursement framework

3.4. Market Dynamics

3.4.1. Market driver analysis

3.4.1.1. Advantage of quick onset upon administration to improve adoption among medical practitioners

3.4.1.2. Cost efficient treatment

3.4.2. Market restraint analysis

3.4.2.1. Lack of skilled staff to monitor delivery device, hinders market growth

3.5. Inhaled Nitric Oxide Delivery System Market Analysis Tools

3.5.1. Industry Analysis - Porter’s

3.5.1.1. Supplier power

3.5.1.2. Buyer power

3.5.1.3. Substitution threat

3.5.1.4. Threat of new entrant

3.5.1.5. Competitive rivalry

3.5.2. PESTEL Analysis

3.5.2.1. Political landscape

3.5.2.2. Technological landscape

3.5.2.3. Economic landscape

3.5.3. Major Deals & Strategic Alliances Analysis

3.5.4. Market Entry Strategies

Chapter 4. Inhaled Nitric Oxide Delivery System: Type Estimates & Trend Analysis

4.1. Definitions and Scope

4.1.1. Pediatrics

4.1.2. Adult

4.2. Inhaled Nitric Oxide Delivery System Market Share, 2024 & 2033

4.3. Segment Dashboard

4.4. Global Inhaled Nitric Oxide Delivery System Market by Type Outlook

4.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following

4.5.1. Pediatrics

4.5.1.1. Pediatrics market estimates and forecast 2021 to 2033

4.5.2. Adult

4.5.2.1. Adult market estimates and forecast 2021 to 2033

Chapter 5. Inhaled Nitric Oxide Delivery System Application Estimates & Trend Analysis

5.1. Definitions and Scope

5.1.1. Hypoxic Respiratory Failure (HRF)

5.1.2. Acute hypoxemic respiratory failure (AHRF)

5.1.3. Others

5.2. Inhaled Nitric Oxide Delivery System Market Share, 2024 & 2033

5.3. Segment Dashboard

5.4. Global Inhaled Nitric Oxide Delivery System Market by Application Outlook

5.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following

5.5.1. Hypoxic Respiratory Failure (HRF)

5.5.1.1. Hypoxic respiratory failure (HRF) market estimates and forecast 2021 to 2033

5.5.2. Acute Hypoxemic Respiratory Failure (AHRF)

5.5.2.1. Acute hypoxemic respiratory failure (AHRF) Market estimates and forecast 2021 to 2033

5.5.3. Other

5.5.3.1. Other market estimates and forecast 2021 to 2033

Chapter 6. Inhaled Nitric Oxide Delivery System: Product Estimates & Trend Analysis

6.1. Definitions and Scope

6.1.1. Disposables

6.1.2. System

6.2. Inhaled Nitric Oxide Delivery System Market Share, 2024 & 2033

6.3. Segment Dashboard

6.4. Global Inhaled Nitric Oxide Delivery System Market by Product Outlook

6.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following

6.5.1. Disposables

6.5.1.1. Disposables market estimates and forecast 2021 to 2033

6.5.2. System

6.5.2.1. System market estimates and forecast 2021 to 2033

Chapter 7. Inhaled Nitric Oxide Delivery System: End-user Estimates & Trend Analysis

7.1. Definitions and Scope

7.1.1. Hospitals

7.1.2. Ambulatory Centers

7.1.3. Clinics

7.2. Inhaled Nitric Oxide Delivery System Market Share, 2024 & 2033

7.3. Segment Dashboard

7.4. Global Inhaled Nitric Oxide Delivery System Market by End User Outlook

7.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following

7.5.1. Hospitals

7.5.1.1. Hospitals market estimates and forecast 2021 to 2033

7.5.2. Ambulatory Centers

7.5.2.1. Ambulatory center market estimates and forecast 2021 to 2033

7.5.3. Clinics

7.5.3.1. Clinics market estimates and forecast 2021 to 2033

Chapter 8. Inhaled Nitric Oxide Delivery System Market: Regional Estimates & Trend Analysis

8.1. Regional market share analysis, 2024 & 2033

8.2. Regional Market Dashboard

8.3. Global Regional Market Snapshot

8.4. Regional Market Share and Leading Players, 2018

8.4.1. North America

8.4.2. Europe

8.4.3. Asia Pacific

8.4.4. Latin America

8.4.5. Middle East and Africa

8.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

8.5.1. North America

8.5.2. Europe

8.5.3. Asia Pacific

8.5.4. Latin America

8.5.5. Middle East and Africa

8.6. Market Size, & Forecasts, Volume and Trend Analysis, 2024 & 2033

8.7. North America

8.7.1. Market estimates and forecast, 2021 - 2033

8.7.2. U.S.

8.7.2.1. Market estimates and forecast, 2021 - 2033

8.7.3. Canada

8.7.3.1. Market estimates and forecast, 2021 - 2033

8.8. Europe

8.8.1. U.K.

8.8.1.1. Market estimates and forecast, 2021 - 2033

8.8.2. Germany

8.8.2.1. Market estimates and forecast, 2021 - 2033

8.8.3. France

8.8.3.1. Market estimates and forecast, 2021 - 2033

8.8.4. Italy

8.8.4.1. Market estimates and forecast, 2021 - 2033

8.8.5. Spain

8.8.5.1. Market estimates and forecast, 2021 - 2033

8.8.6. Norway

8.8.6.1. Market estimates and forecast, 2021 - 2033

8.8.7. Sweden

8.8.7.1. Market estimates and forecast, 2021 - 2033

8.8.8. Russia

8.8.8.1. Market estimates and forecast, 2021 - 2033

8.9. Asia Pacific

8.9.1. Japan

8.9.1.1. Market estimates and forecast, 2021 - 2033

8.9.2. China

8.9.2.1. Market estimates and forecast, 2021 - 2033

8.9.3. India

8.9.3.1. Market estimates and forecast, 2021 - 2033

8.9.4. Thailand

8.9.4.1. Market estimates and forecast, 2021 - 2033

8.9.5. South Korea

8.9.5.1. Market estimates and forecast, 2021 - 2033

8.9.6. Australia

8.9.6.1. Market estimates and forecast, 2021 - 2033

8.10. Latin America

8.10.1. Brazil

8.10.1.1. Market estimates and forecast, 2021 - 2033

8.10.2. Mexico

8.10.2.1. Market estimates and forecast, 2021 - 2033

8.10.3. Argentina

8.10.3.1. Market estimates and forecast, 2021 - 2033

8.11. MEA

8.11.1. South Africa

8.11.1.1. Market estimates and forecast, 2021 - 2033

8.11.2. Saudi Arabia

8.11.2.1. Market estimates and forecast, 2021 - 2033

8.11.3. UAE

8.11.3.1. Market estimates and forecast, 2021 - 2033

8.11.4. Turkey

8.11.4.1. Market estimates and forecast, 2021 - 2033

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis, By Key Market Participants

9.2. Company/Competition Categorization

9.2.1. Innovators

9.3. Vendor Landscape

9.3.1. List of key distributors and channel partners

9.3.2. Key customers

9.3.3. Key company market share analysis, 2018

9.3.4. Mallinckrodt Pharmaceuticals

9.3.4.1. Company overview

9.3.4.2. Financial performance

9.3.4.3. Product benchmarking

9.3.4.4. Strategic initiatives

9.3.5. Getinge

9.3.5.1. Company overview

9.3.5.2. Financial performance

9.3.5.3. Product benchmarking

9.3.5.4. Strategic initiatives

9.3.6. Vero Biotech

9.3.6.1. Company overview

9.3.6.2. Financial performance

9.3.6.3. Product benchmarking

9.3.6.4. Strategic initiatives

9.3.7. Linde

9.3.7.1. Company overview

9.3.7.2. Financial performance

9.3.7.3. Product benchmarking

9.3.7.4. Strategic initiatives

9.3.8. Beyond Air

9.3.8.1. Company overview

9.3.8.2. Financial performance

9.3.8.3. Product benchmarking

9.3.8.4. Strategic initiatives

9.3.9. SLE

9.3.9.1. Company overview

9.3.9.2. Financial performance

9.3.9.3. Product benchmarking

9.3.9.4. Strategic initiatives

9.3.10. Nu Med

9.3.10.1. Company overview

9.3.10.2. Financial performance

9.3.10.3. Product benchmarking

9.3.10.4. Strategic initiatives

9.3.11. Bellerophon Therapeutics

9.3.11.1. Company overview

9.3.11.2. Financial performance

9.3.11.3. Product benchmarking

9.3.11.4. Strategic initiatives

9.3.12. Air Liquide Healthcare

9.3.12.1. Company overview

9.3.12.2. Financial performance

9.3.12.3. Product benchmarking

9.3.12.4. Strategic initiatives

9.3.13. Circassia Pharmaceuticals

9.3.13.1. Company overview

9.3.13.2. Financial performance

9.3.13.3. Product benchmarking

 

9.3.13.4. Strategic initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers